Key result
IGFBP2 exhibits conflicting roles in cancer by acting as both an oncogene and tumor suppressor.
Understanding the dual role of IGFBP2 in cancer requires accounting for confounding factors such as BMI, proteolysis, and the tumor microenvironment.
The role of insulin-like growth factor binding protein 2 (IGFBP2) in cancer is unclear. In general, IGFBP2 is considered to be oncogenic and its expression is often observed to be elevated in cancer. However, there are a number of conflicting reports in vitro and in vivo where IGFBP2 acts in a tumor suppressor manner. In this mini-review, we discuss the factors influencing the variation in IGFBP2 expression in cancer and our interpretation of these findings.
No takes yet. Share an insight, caveat, or question.
Pickard et al. (2015) conducted a review in Cancer. IGFBP2 was evaluated. IGFBP2 exhibits conflicting roles in cancer, acting as both an oncogene and a tumor suppressor depending on various influencing factors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: